PMID- 35524867
OWN - NLM
STAT- MEDLINE
DCOM- 20220719
LR  - 20220818
IS  - 1573-0646 (Electronic)
IS  - 0167-6997 (Linking)
VI  - 40
IP  - 4
DP  - 2022 Aug
TI  - Identifification of a novel LDLR-RET Fusion in Lung Adenocarcinoma.
PG  - 858-860
LID - 10.1007/s10637-022-01246-2 [doi]
AB  - BACKGROUND: REarranged during Transfection (RET) gene fusion is one of the common 
      oncogenic variants detectable in non-small cell lung cancer (NSCLC). The feature 
      of most oncogenic RET gene fusion cases is that RET tyrosine kinase domain is 
      retained in fusions and the partner gene includes a coiled-coil or LIS1 homology 
      domain. However, only a few studies reported about the exceptional form of RET 
      fusion in NSCLC so far. METHODS: Targeted next-generation sequencing (NGS) and 
      fluorescence in situ hybridization (FISH) were performed on resected cancerous 
      tissue. RESULTS: A rare form of RET fusion was identified in a 45 year-old 
      Chinese female patient, in which exon 1-4 of LDLR fused with exon 12-21 of RET. 
      The result was validated by FISH. CONCLUSIONS: This novel form of RET fusion in 
      NSCLC is reported for the first time worldwide, offering a new treatment option 
      for the patient with the possibility of using RET-selective inhibitors.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Shi, Guanglin
AU  - Shi G
AD  - Nantong Hospital of Shanghai University, 226013, Nanting, Nantong, Jiangsu, 
      China.
FAU - Luo, Yuyan
AU  - Luo Y
AD  - Nantong Hospital of Shanghai University, 226013, Nanting, Nantong, Jiangsu, 
      China.
FAU - Yu, Zhaonan
AU  - Yu Z
AD  - Hangzhou D.A. Medical Laboratory, 310030, Hangzhou, China.
FAU - Wang, Yue
AU  - Wang Y
AD  - Hangzhou D.A. Medical Laboratory, 310030, Hangzhou, China.
FAU - Zhu, Bojin
AU  - Zhu B
AUID- ORCID: 0000-0002-9922-2337
AD  - The Prople's Hosptial of Hai', An, 17zhongba Road, Hai'An 226600, 226600, 
      Jiangsu, Jiangsu, China. bojinzhu2022@163.com.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20220507
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-ret)
RN  - EC 2.7.10.1 (RET protein, human)
SB  - IM
MH  - *Adenocarcinoma of Lung/genetics
MH  - *Carcinoma, Non-Small-Cell Lung/pathology
MH  - Female
MH  - Gene Fusion
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Lung Neoplasms/drug therapy/genetics/pathology
MH  - Oncogene Proteins, Fusion/genetics
MH  - Protein Kinase Inhibitors
MH  - Proto-Oncogene Proteins c-ret/genetics
OTO - NOTNLM
OT  - LDLR-RET
OT  - Partner gene
OT  - RET fusion
OT  - REarranged during transfection
OT  - Therapeutic target
EDAT- 2022/05/08 06:00
MHDA- 2022/07/20 06:00
CRDT- 2022/05/07 11:18
PHST- 2022/02/07 00:00 [received]
PHST- 2022/04/04 00:00 [accepted]
PHST- 2022/05/08 06:00 [pubmed]
PHST- 2022/07/20 06:00 [medline]
PHST- 2022/05/07 11:18 [entrez]
AID - 10.1007/s10637-022-01246-2 [pii]
AID - 10.1007/s10637-022-01246-2 [doi]
PST - ppublish
SO  - Invest New Drugs. 2022 Aug;40(4):858-860. doi: 10.1007/s10637-022-01246-2. Epub 
      2022 May 7.